BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shao M, Ye C, Bayliss G, Zhuang S. New Insights Into the Effects of Individual Chinese Herbal Medicines on Chronic Kidney Disease. Front Pharmacol 2021;12:774414. [PMID: 34803715 DOI: 10.3389/fphar.2021.774414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wo G, Zhu Z, Fang Z, Chen X, Liang M, Wang Y, Shao X, Shen H, Tang J. Dihydrotanshinone I: A Target for STAT3 in the Therapy of Tamoxifen‐Resistant Breast Cancer. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202203082] [Reference Citation Analysis]
2 Zhang N, Guan C, Liu Z, Li C, Yang C, Xu L, Niu M, Zhao L, Zhou B, Che L, Wang Y, Xu Y. Calycosin attenuates renal ischemia/reperfusion injury by suppressing NF-κB mediated inflammation via PPARγ/EGR1 pathway. Front Pharmacol 2022;13:970616. [DOI: 10.3389/fphar.2022.970616] [Reference Citation Analysis]
3 He F, Wang Y, Chen Y, Huang W, Li Z, Zhang C. Sepsis-induced AKI: From pathogenesis to therapeutic approaches. Front Pharmacol 2022;13:981578. [DOI: 10.3389/fphar.2022.981578] [Reference Citation Analysis]
4 Yang L, Wang B, Ma L, Fu P. Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease. Front Pharmacol 2022;13:971032. [DOI: 10.3389/fphar.2022.971032] [Reference Citation Analysis]
5 Wu W, Cheng R, Boucetta H, Xu L, Pan JR, Song M, Lu YT, Hang TJ. Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin-Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity. Front Pharmacol 2022;13:910923. [PMID: 35754482 DOI: 10.3389/fphar.2022.910923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, Feng Z. The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment. Front Pharmacol 2022;13:780496. [PMID: 35350750 DOI: 10.3389/fphar.2022.780496] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Yu X, Sun Q, Zhang Y, Zou L, Zhao Y. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol 2022;13:860588. [DOI: 10.3389/fphar.2022.860588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]